NASDAQ:MCRB
Seres Therapeutics, Inc.
Seres Therapeutics, Inc.'s revenue was $789,000 in fiscal 2025. Free cash flow was $865,000, 109.6% of revenue, and the diluted share count rose 14.2%.Summary generated from Seres Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 12, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$789,000
Revenue growthn/a
Revenue, 5-yr CAGR−52.7%
Gross marginn/a
Operating margin−11910.1%
Net margin721.9%
ROICn/a
Return on equity19.6%
Debt / equityn/a
Free cash flow$865,000
FCF margin109.6%
Share count change+14.2%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 145 | 7 | 0 | 0 | 1 |
| Operating income | −64 | −180 | −195 | −121 | −94 |
| Net income | −66 | −250 | −114 | 0 | 6 |
| Free cash flow | −3 | −239 | −125 | −149 | 1 |
Recent filings
- 4Insider transaction report
Aug 18, 2026 - 4Insider transaction report
Aug 18, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 5, 2026 - 8-KResults of operations and financial condition
Aug 5, 2026 - 8-KEntry into a material agreement
Aug 4, 2026 - 8-KDirector or officer change
Jul 8, 2026 - 8-KRegulation FD disclosure
Jul 8, 2026 - 8-KEntry into a material agreement
Jun 5, 2026